Clinical trials
DelveInsight's "Gout Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Gout pipeline landscape. The Gout Pipeline report covers the Gout Pipeline drug profiles, including clinical and nonclinical stage products, and highlights the inactive pipeline products in this space.
Clinical trials
The global influenza pipeline landscape is a highly competitive space, with 120+ companies and 120+ pipeline drugs in development. DelveInsight's "Influenza Pipeline Insight 2025" report provides comprehensive insights into the pharmaceutical and biotechnology companies, therapies, and clinical trials involved in the development of treatments for influenza.
Clinical trials
IgA nephropathy (IgAN) is the most common primary glomerular disease that can progress to end-stage renal failure (ESRD), with a subset of patients experiencing rapid disease progression and renal failure within years if not treated. Recent advancements in the IgA Nephropathy pipeline have led to the development of innovative therapies,
AIDS treatment
The European AIDS Treatment Group has published promising results from a phase 2 trial combining lenacapavir (LEN) and two broadly neutralizing antibodies (bNAbs), teropavimab (TAB) and zinlirvimab (ZAB). The study, presented at EACS 2025, found that this combination produced a slightly lower average increase in CD4+ counts compared to a
Diseases
Researchers are investigating the diagnostic performance of [Ã ü¹F]FAPI-74 PET/CT in detecting metastatic disease in adults with gastric or esophageal cancer. A Phase 3 clinical trial, sponsored by SOFIE, aims to enroll 200 participants from the USA to assess the clinical utility of this imaging modality. The
Diseases
Researchers at the University of [Blank] have been conducting a clinical trial to assess the effectiveness of [Ã ü¹F]FAPI-74 PET/CT in detecting metastatic pancreatic ductal adenocarcinoma. The trial, which aims to recruit 200 participants from the USA, is currently not open for recruiting. The study will evaluate
Medical research
In a groundbreaking effort to improve patient care, Yangpu District Central Hospital of Shanghai has initiated a clinical trial to examine the effectiveness of an innovative health education technology program. The program, based on the transtheoretical model, aims to enhance self-care ability, reduce the incidence of complications, and increase patient
Diseases
A Phase 1 interventional clinical trial, led by principal investigator Eben Rosenthal, MD, has been initiated at the Vanderbilt-Ingram Cancer Center to evaluate the safety, tolerability, and diagnostic performance of a novel PET imaging agent, [18F]NOTA-ABY030, in patients with head and neck squamous cell carcinoma (HNSCC). The trial aims
Diseases
Regeneron Pharmaceuticals has launched an interventional clinical trial, Phase 1, aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of intrathecally administered ALN-SNCA in participants with early Parkinson's disease. The trial, which is not yet open for recruiting, will involve 46 participants from the
Clinical trials
Researchers at the University of Wisconsin-Madison, in collaboration with biotechnology company Aspen Neuroscience, have made significant progress in developing a novel cell therapy for Parkinson's disease. The treatment involves growing new brain cells from a patient's own cells, which are then grafted into key areas of
Medical research
A clinical trial has been registered in Australia to study the effectiveness of continuous glucose monitoring (CGM) and a culturally appropriate primary care pharmacist prescriber model of care in managing type 2 diabetes in Pacific adults. The trial, led by Prof Ben Wheeler, aims to investigate whether the use of
Diseases
Lundbeck's pipeline developments for amlenetug, a novel investigational molecule for treating Multiple System Atrophy (MSA), will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders in Honolulu, Hawaii. Amlenetug, a human monoclonal antibody, targets pathological aggregations of the protein a-synuclein in the
